federal food and drug administration dermatologic drugs advisory committee voted unanimously upjohn rogaine baldness drug was safe and effective panel recommended fda approve rogaine for marketing united states long accompanying packaging and promotional materials disclose product has only limited effect male pattern baldness five outside experts attending today fda committee meeting seemed less concerned about rogaine safety after outside consultant told them drug appears quite safe normal male population consultant ohio university professor medicine carl leier said rogaine side effects were minimal based study 000 individuals have been getting drug canada was approved for marketing last year canadian record quite good terms side effects leier said experts urged fda require warning drug packaging patients monitored for heart effects while taking drug such irregular heart beats changes heart rate palpitations and fluid retention body rogaine whose chemical name minoxidil has already been approved fda when taken orally high blood pressure drug but upjohn now seeking agency approval male baldness treatment when put directly skin liquid form upjohn has previously claimed when applied scalp little rogaine was absorbed into bloodstream heart but panel members concluded amount absorbed merited physician monitoring patients taking drug under questioning panel members upjohn official richard villez acknowledged drug clinical trials produced moderate hair growth crown head only about pct after months also acknowledged discontinuing treatment would new hair fall out upjohn problem have tremendous placebo effect panel member paul bergstresser university texas told meeting said patients administered placebo during clinical trials typically had about half much new hair growth did individuals treated with rogaine may patients months before can tell whether thay benefiting from drug said canada year treatment costs about 550 640 dlrs upjohn official said price would set for drug market until was approved for sale during trials drug was found have bizarre side effect some individuals caused sexual dysfunction known exagerrated erection stewart ehrreich former fda official conducted safety review rogaine before leaving agency said researchers had found number cases patients had exagerrated erections drug said this was common effect for drugs same class rogaine called vaso dilators fda officials said could prediction when rogaine might approved for marketing following vote panel member robert stern boston dermatologist said upjohn statistics had exaggerated effect drug said about five will have substantial clinical effect which defined significant growth new hair made patient actually better urged insurance companies not cover cost rogaine treatment order preserve scarce medical fund resources would hope insurance companies will strong line this not product will reimburse for stern told reporters think this drug has some application for some people and think some people will find worth expense said but said individuals should required pay for treatment out personal funds stern estimated more 100 000 american men already using minoxidil scalps outside law grinding blood pressure pill and dissolving solvent reuter 